Oslo, 26 May 2023: Reference is made to Aker BioMarine ASA's stock exchange
announcement on 9 May 2023, regarding the result of the offer under the Employee
Share Purchase Program and the related share capital increase. 
 
The share capital increase of NOK pertaining to the Employee Share Purchase
Program has today been registered with the Norwegian Register of Business
Enterprises (Nw.: Foretaksregisteret). The new registered share capital of the
company is NOK 526 036 488 divided into 87 672 748 shares, each with a par value
of NOK 6.00. Upon registration with the Norwegian Central Securities Depository
(VPS), the new shares will be listed on the Oslo Stock Exchange.
 
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.
 
For further information, please contact
Katrine Klaveness
CFO 
Mobile: +47 991 58 915 
Email: Katrine.Klaveness@akerbiomarine.com
 
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for pharma, consumer health and
wellness as well as animal nutrition. The company has a strong position in its
industry and is the world's leading supplier of krill, the natural, powerful and
health promoting source of nutrients from the pristine waters of Antarctica.
Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is
available at www.akerbiomarine.com.